Generalizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States

Glucagon Like Peptide ◽

1424-P: Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials to the Type 2 Diabetes Population in China

Diabetes ◽

10.2337/db20-1424-p ◽

2020 ◽

Vol 69 (Supplement 1) ◽

pp. 1424-P

Author(s):

XIAOLING CAI ◽

LIN ZHANG ◽

HAIYA WU ◽

LI HUO ◽

XIAO MA ◽

...

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Cardiovascular Outcome ◽

Glucagon Like Peptide ◽

Retrospective Study of Adherence to Glucagon-like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes Mellitus in the United States

Advances in Therapy ◽

10.1007/s12325-014-0166-0 ◽

2014 ◽

Vol 31 (11) ◽

pp. 1119-1133 ◽

Cited By ~ 45

Author(s):

Stephen S. Johnston ◽

Hiep Nguyen ◽

Eugene Felber ◽

Katherine Cappell ◽

James K. Nelson ◽

...

Keyword(s):

Diabetes Mellitus ◽

United States ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

The United States ◽

Agonist Therapy ◽

Glucagon Like Peptide ◽

Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials

Canadian Journal of Diabetes ◽

10.1016/j.jcjd.2019.08.011 ◽

2020 ◽

Vol 44 (1) ◽

pp. 68-77 ◽

Cited By ~ 4

Author(s):

Elodie M. Varin ◽

Brent A. McLean ◽

Julie A. Lovshin

Keyword(s):

Type 2 Diabetes ◽

Adult Patients ◽

Cardiovascular Outcome ◽

Receptor Agonists ◽

Glucagon Like Peptide ◽

Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States

Patient Preference and Adherence ◽

10.2147/ppa.s277676 ◽

2020 ◽

Vol Volume 14 ◽

pp. 2337-2345

Author(s):

Tracey Weiss ◽

Richard D Carr ◽

Sampriti Pal ◽

Lingfeng Yang ◽

Baanie Sawhney ◽

...

Keyword(s):

Diabetes Mellitus ◽

United States ◽

Type 2 Diabetes ◽

Real World ◽

The United States ◽

Receptor Agonists ◽

Glucagon Like Peptide ◽

Short-Term Cost-Effectiveness of Glucagon-Like Peptide-1 Receptor Analogues Versus Sodium-Glucose Cotransporter-2 Inhibitors as Second-Line Add-On Therapy for Type 2 Diabetes in the United States

Value in Health ◽

10.1016/j.jval.2018.04.504 ◽

2018 ◽

Vol 21 ◽

pp. S75

Author(s):

N Ruiz-Negron ◽

J Menon ◽

BK Bellows

Keyword(s):

United States ◽

Type 2 Diabetes ◽

Cost Effectiveness ◽

The United States ◽

Second Line ◽

Short Term ◽

Sodium Glucose Cotransporter ◽

Glucagon Like Peptide ◽

CARDIOVASCULAR BENEFIT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN FEMALE PATIENTS WITH TYPE 2 DIABETES MELLITUS: A META-ANALYSIS OF RECENT CARDIOVASCULAR OUTCOME TRIALS

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(19)30847-2 ◽

2019 ◽

Vol 73 (9) ◽

pp. 239

Author(s):

David Aguilar ◽

Efstratios Koutroumpakis ◽

Heinrich Taegtmeyer

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Meta Analysis ◽

Cardiovascular Outcome ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Cardiovascular Benefit

Comparative Persistency with Newer agents used to Treat Type 2 Diabetes (T2dm) In the united states: canagliflozin Versus Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors and Glucagon-Like Peptide-1 (Glp-1) agonists

Value in Health ◽

10.1016/j.jval.2015.03.398 ◽

2015 ◽

Vol 18 (3) ◽

pp. A68-A69 ◽

Cited By ~ 2

Author(s):

J. Diels ◽

C. Neslusan

Keyword(s):

United States ◽

Type 2 Diabetes ◽

The United States ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Glucagon Like Peptide ◽

Comparative safety of glucagon like peptide‑1 receptor agonists in patients with type 2 diabetes: a network meta-analysis of cardiovascular outcome trials

10.37766/inplasy2020.8.0122 ◽

2020 ◽

Author(s):

Chuanjun Zhuo ◽

Hongjun Tian ◽

Lina Wang ◽

Xiangyang Gao ◽

Li Ding ◽

...

Keyword(s):

Type 2 Diabetes ◽

Meta Analysis ◽

Cardiovascular Outcome ◽

Receptor Agonists ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Comparative Safety

Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus

Diabetes Therapy ◽

10.1007/s13300-021-01079-x ◽

2021 ◽

Author(s):

Xiaoling Cai ◽

Linong Ji

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Cardiovascular Outcome ◽

Chinese Patients ◽

Receptor Agonists ◽

Glucagon Like Peptide ◽

Abstract P077: Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes in Black Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Recent Cardiovascular Outcome Trials

Circulation ◽

10.1161/circ.139.suppl_1.p077 ◽

2019 ◽

Vol 139 (Suppl_1) ◽

Author(s):

Efstratios Koutroumpakis ◽

Heinrich Taegtmeyer ◽

David Aguilar

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Meta Analysis ◽

Cardiovascular Outcome ◽

Black Patients ◽

Glucagon Like Peptide ◽